Literature DB >> 15914590

Cyclosporin a affects signaling events differentially in human gingival fibroblasts.

A Bostrom1, H Bharath, A Saulewicz, A S Narayanan.   

Abstract

Gingival overgrowth is a common side-effect of the administration of cyclosporin A (CSA), phenytoin, and calcium blockers. To identify the signaling mechanisms possibly involved in the overgrowth, we examined how CSA affects the activities of MAP kinases and transcription factors in human gingival fibroblasts (HGF). The HGF were treated with CSA and TNF-alpha or PDGF. DNA-binding activity of NFAT, NFkappaB, and AP-1 transcription factors was determined by gel shift assay, and JNK, p38, and ERK1 and ERK2 activation was assessed by Western blot analysis of immunoprecipitates. The CSA inhibited NFAT, NFkappaB, and p38 and JNK activities; however, ERK1 and ERK2 were not affected significantly. AP-1 activity increased approximately 4.5-fold. Our results indicate that CSA affects signaling molecules in HGF differently from other cell types, and that a CSA-induced increase in AP-1 activity may affect the expression of fibrogenic molecules in gingiva and promote gingival overgrowth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15914590     DOI: 10.1177/154405910508400609

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  3 in total

1.  Lip hypertrophy due to cyclosporine therapy.

Authors:  Kanika Kapoor; Abhijeet Saha; N K Dubey
Journal:  Clin Exp Nephrol       Date:  2013-04-25       Impact factor: 2.801

2.  Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.

Authors:  Masashi Miyazaki; Yosuke Fujikawa; Chikahiro Takita; Hiroshi Tsumura
Journal:  Clin Rheumatol       Date:  2006-04-04       Impact factor: 2.980

Review 3.  Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis.

Authors:  R S Brown; P R Arany
Journal:  Oral Dis       Date:  2014-08-07       Impact factor: 3.511

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.